This cohort study evaluates whether there is a difference in kidney recovery outcomes following angiotensin receptor-neprilysin inhibitor (ARNI) vs angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) therapy among patients with malignant hypertension–associated thrombotic microangiopathy. Here, ACE is linked to Genetic thrombotic microangiopathy.